CLINICAL TRIALS PROFILE FOR NEVIRAPINE
✉ Email this page to a colleague
All Clinical Trials for NEVIRAPINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000634 ↗ | A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children | Completed | Boehringer Ingelheim | N/A | 1969-12-31 | To generate initial information on the pharmacokinetics (blood levels) and dose proportionality of nevirapine (BI-RG-587) plasma levels in HIV-infected children; to assess the safety and tolerance of single rising oral doses of nevirapine in HIV-infected children; and to confirm that the single doses that achieve certain plasma levels in adults achieve similar levels in HIV-infected children. Test tube studies have shown that nevirapine (BI-RG-587) inhibits replication (reproduction) of HIV. Nevirapine works with zidovudine (AZT) and is active against strains of the virus that are resistant to AZT. Studies of the drug in HIV-infected adults showed no serious adverse effects. |
| NCT00000634 ↗ | A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | 1969-12-31 | To generate initial information on the pharmacokinetics (blood levels) and dose proportionality of nevirapine (BI-RG-587) plasma levels in HIV-infected children; to assess the safety and tolerance of single rising oral doses of nevirapine in HIV-infected children; and to confirm that the single doses that achieve certain plasma levels in adults achieve similar levels in HIV-infected children. Test tube studies have shown that nevirapine (BI-RG-587) inhibits replication (reproduction) of HIV. Nevirapine works with zidovudine (AZT) and is active against strains of the virus that are resistant to AZT. Studies of the drug in HIV-infected adults showed no serious adverse effects. |
| NCT00000649 ↗ | An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3) | Completed | Boehringer Ingelheim | Phase 1 | 1969-12-31 | To assess the safety and tolerance of multiple oral doses of nevirapine in combination with zidovudine (AZT); to get information on the pharmacokinetics (blood levels) and dose proportionality of nevirapine/AZT with multiple dosing; to characterize the pattern of virological activity in vivo (in humans) of nevirapine in combination with AZT; to determine whether development of resistance to either drug is slowed by the use of the combination. Drugs now used in treatment for patients with AIDS show some toxicity which limits their usefulness. In addition, with long-term treatment with AZT, there is evidence of virus resistance to the drug. Compounds that are more effective and less toxic than those in present use would be beneficial, especially if they are active against AZT-resistant viruses. Nevirapine has shown in vitro (test tube studies) activity in inhibiting HIV replication (reproduction). In vitro studies have shown that nevirapine and AZT work together to inhibit HIV replication. |
| NCT00000747 ↗ | An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3 | Completed | Boehringer Ingelheim | Phase 2 | 1969-12-31 | Primary: To evaluate the rate of development of resistance to nevirapine in HIV-1 infected individuals. To evaluate safety of nevirapine in HIV-1 infected individuals with CD4 counts greater than or equal to 500 cells/mm3. Secondary: To evaluate the effect of nevirapine on surrogate markers. The anti-HIV agent nevirapine is associated with rapid emergence of resistance when administered alone or in combination with zidovudine to HIV-infected patients with CD4 counts <= 400 cells/mm3. In persons with less advanced HIV disease and less viral burden, the emergence of resistance may be delayed, thus permitting evaluation for beneficial effect in a population where there is currently no established therapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NEVIRAPINE
Condition Name
Clinical Trial Locations for NEVIRAPINE
Trials by Country
Clinical Trial Progress for NEVIRAPINE
Clinical Trial Phase
Clinical Trial Sponsors for NEVIRAPINE
Sponsor Name
| Sponsor Name for NEVIRAPINE | |
| Sponsor | Trials |
| National Institute of Allergy and Infectious Diseases (NIAID) | 65 |
| Boehringer Ingelheim | 48 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 30 |
| [disabled in preview] | 9 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
